Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...
Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, ...
Durability of immune checkpoint inhibitor (ICI) response following treatment discontinuation in advanced merkel cell carcinoma (MCC). The 15-gene expression profile test is independent from PRAME and ...
Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...
The HIV regulatory protein transactivator of transcription (Tat) is a viral protein believed to play a key role in the neurotoxicity and cognitive impairment seen in HIV-associated neurocognitive ...
Saniona AB has selected its proprietary GABA-A α5 negative allosteric modulator lead compound, SAN-2465, as a clinical candidate for major depressive disorder following encouraging results in a rodent ...
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback